Inflammatory Mechanisms Contributing to Pancreatic Cancer Development

Buckminster Farrow

Yuko Sugiyama

Andy Chen

Ekong Uffort

William Nealon

B Evers

From the Department of *Surgery and †Sealy Center for Cancer Cell Biology, The University of Texas Medical Branch, Galveston, TX 77555–0536.

Abstract

Objective:

Pancreatic cancer is the most deadly of all gastrointestinal (GI) malignancies, yet relatively little is known regarding mechanisms of tumor development including the role of inflammation.

Summary Background Data:

Chronic pancreatitis (CP) increases the risk of developing cancer by 10- to 20-fold; mediators of the chronic inflammatory process and the surrounding fibrotic stroma likely support a transformation to malignancy, yet the exact mechanisms remain undefined. The purpose of our present study was to determine potential inflammatory components in epithelial and stromal cells that may contribute to both CP and pancreatic cancers.

Methods:

Specimens of normal pancreas, CP, and pancreatic cancer were examined using laser-capture microdissection (LCM), gene array, and immunohistochemistry.

Results:

Gene array analysis from LCM-dissected tissues demonstrated: (i) increased expression of interleukin-8 (IL-8), an activator of the inflammatory factor nuclear factor-κB (NF-κB), and (ii) decreased expression of IκB (an inhibitor of NF-κB) in CP ductal cells compared with normal ducts. Compared with CP, cancers demonstrated: (i) increased expression of tumor related genes including S100A4, cyclin E1, and epidermal growth factor (EGF) receptor, and (ii) expression of matrix metalloproteinase 2, a pro-invasive factor for tumor cells, which was not present in the CP stroma. Increased staining of both the p50 NF-κB subunit and IKKα kinase (a protein that allows activation of NF-κB) was noted in CP and cancers.

Conclusions:

Our results demonstrate that similar inflammatory components and downstream effectors are present in CP and pancreatic cancers. Importantly, these findings suggest that a common pathway for pancreatic cancer development may be through a chronic inflammatory process including stroma formation. These findings may lead to novel strategies for pancreatic cancer prophylaxis based on inhibition of inflammatory mediators.

Abstract

Footnotes

Supported by grants from the National Institutes of Health (RO1 DK48498, R37AG10885, PO1 DK35608, and T32 DK07639).

Reprints: B. Mark Evers, MD, Department of Surgery, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0536. E-mail: ude.bmtu@srevem.

Footnotes

REFERENCES

References

1. Marjolin J-NUlce $\ddot{r}$ e. Dictionnaire de Medecine. Vol 21. Pratique, 1828.
2. Adelstein P, Baldwin JA, Fedrich JCancers of the large bowel: associated disorders in individuals. Cancer. 1979;43:2553–2557. [[PubMed]
3. Konig H, Hermanek P, Rosch WClinical conference: Unusual course of chronic colitis. Acta Hepatogastroenterol (Stuttg). 1976;23:227–231. [[PubMed]
4. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–1233. [[PubMed]
5. Munkholm PReview article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):1–5. [[PubMed]
6. Eaden JReview article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(Suppl 2):15–21. [[PubMed]
7. Ryan BM, Russel MG, Langholz E, et alAminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol. 2003;98:1682–1687. [[PubMed]
8. Jemal A, Murray T, Samuels A, et alCancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26. [[PubMed]
9. Yeo CJ, Cameron JL. Exocrine pancreas. In: Townsend CM Jr, Beauchamp RD, Evers BM, et al, eds. Sabiston Textbook of Surgery. The Biological Basis of Modern Surgical Practice. Philadelphia: W. B. Saunders Company; 2001:1112–1143. [PubMed]
10. Lillemoe KD, Yeo CJ, Cameron JLPancreatic cancer: state-of-the-art care. CA Cancer J Clin. 2000;50:241–268. [[PubMed]
11. Hruban RH, Wilentz RE, Kern SEGenetic progression in the pancreatic ducts. Am J Pathol. 2000;156:1821–1825.
12. Hansel DE, Kern SE, Hruban RHMolecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet. 2003;4:237–256. [[PubMed]
13. House MG, Herman JG, Guo MZ, et alAberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg. 2003;238:423–432.
14. Jimenez RE, Warshaw AL, Z’Graggen K, et alSequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg. 1999;230:501–509; discussion 509–511.
15. Howes N, Neoptolemos JPRisk of pancreatic ductal adenocarcinoma in chronic pancreatitis. Gut. 2002;51:765–766.
16. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328:1433–1437. [[PubMed]
17. Otsuki MChronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. J Gastroenterol. 2003;38:315–326. [[PubMed]
18. Shimizu K, Shiratori K, Hayashi N, et alThiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis. Pancreas. 2002;24:184–190. [[PubMed]
19. Farrow B, Evers BMInflammation and the development of pancreatic cancer. Surg Oncol. 2002;10:153–169. [[PubMed]
20. Rayet B, Gelinas CAberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938–6947. [[PubMed]
21. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–1659. [[PubMed]
22. Thomas RP, Farrow BJ, Kim S, et alSelective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery. 2002;132:127–134. [[PubMed]
23. Ethridge RT, Hashimoto K, Chung DH, et alSelective inhibition of NF-κB attenuates the severity of cerulein-induced acute pancreatitis. J Am Coll Surg. 2002;195:497–505. [[PubMed]
24. Schwartz SA, Hernandez A, Mark Evers BThe role of NF-κB/INF-κB proteins in cancer: implications for novel treatment strategies. Surg Oncol. 1999;8:143–153. [[PubMed]
25. Sugiyama Y, Shingo D, Yoshida Y, et alA large-scale gene expression comparison of microdissected, small-sized endometrial cancers with or without hyperplasia matched to same-patient normal tissue. Clin Cancer Res. 2003; In press. [[PubMed]
26. Sugiyama Y, Sugiyama K, Hirai Y, et alMicrodissection is essential for gene expression profiling of clinically resected cancer tissues. Am J Clin Pathol. 2002;117:109–116. [[PubMed]
27. Shimada T, Terano AChemokine expression in Helicobacter pylori-infected gastric mucosa. J Gastroenterol. 1998;33:613–617. [[PubMed]
28. Baldwin AS JrSeries introduction: the transcription factor NF-κB and human disease. J Clin Invest. 2001;107:3–6.
29. Liptay S, Weber CK, Ludwig L, et alMitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer. Int J Cancer. 2003;105:735–746. [[PubMed]
30. Rosty C, Ueki T, Argani P, et alOverexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol. 2002;160:45–50.
31. Matsuda K, Idezawa T, You XJ, et alMultiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res. 2002;62:5611–5617. [[PubMed]
32. Koshiba T, Hosotani R, Wada M, et alDetection of matrix metalloproteinase activity in human pancreatic cancer. Surg Today. 1997;27:302–304. [[PubMed]
33. Philip S, Bulbule A, Kundu GCOsteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κB-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001;276:44926–44935. [[PubMed]
34. Balkwill F, Mantovani AInflammation and cancer: back to Virchow? Lancet. 2001;357:539–545. [[PubMed]
35. Wang W, Abbruzzese JL, Evans DB, et alThe nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119–127. [[PubMed]
36. McDade TP, Perugini RA, Vittimberga FJ Jr, et alSalicylates inhibit NF-κB activation and enhance TNF-α-induced apoptosis in human pancreatic cancer cells. J Surg Res. 1999;83:56–61. [[PubMed]
37. Kim H, Seo JY, Kim KHNF-κB and cytokines in pancreatic acinar cells. J Korean Med Sci. 2000;15(Suppl):S53–S54.
38. Yamamoto Y, Gaynor RBTherapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107:135–142.
39. Huang ZQ, Buchsbaum DJ, Raisch KP, et alDifferential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J Surg Res. 2003;111:274–283. [[PubMed]
40. Ozawa F, Friess H, Tempia-Caliera A, et alGrowth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen. 2001;21:27–44. [[PubMed]
41. Greten FR, Wagner M, Weber CK, et al. TGFα transgenic mice. A model of pancreatic cancer development. Pancreatology. 2001;1:363–368. [[PubMed]
42. Matsuyama Y, Takao S, Aikou TComparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol. 2002;80:105–110. [[PubMed]
43. Yoon SO, Park SJ, Yoon SY, et alSustained production of H(2)O(2) activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-κB pathway. J Biol Chem. 2002;277:30271–30282. [[PubMed]
44. Hashimoto K, Ethridge RT, Evers BMPeroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. Int J Gastrointest Cancer. 2002;32:7–22. [[PubMed]
45. Ellenrieder V, Alber B, Lacher U, et alRole of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer. 2000;85:14–20. [[PubMed]
46. Hedin KEChemokines: new, key players in the pathobiology of pancreatic cancer. Int J Gastrointest Cancer. 2002;31:23–29. [[PubMed]
47. Maisonneuve P, Lowenfels ABChronic pancreatitis and pancreatic cancer. Dig Dis. 2002;20:32–37. [[PubMed]
48. Hitt EAspirin may lower risk of pancreatic cancer. Lancet Oncol. 2002;3:518. [[PubMed]